STOCK TITAN
  1. Home
  2. Sec-filings
  3. HIMS
  4. [Form 4] Hims & Hers Health, Inc. Insider Trading Activity

[Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Hims & Hers Health (HIMS) CEO and 10% owner Andrew Dudum reported multiple insider transactions on 10/16/2025 under a Rule 10b5-1 plan adopted on August 28, 2024. He exercised stock options at an exercise price of $2.43 and sold shares in several tranches at weighted average prices disclosed within ranges, including $62.50–$62.87, $62.215–$63.13, and $63.31–$63.59.

Reported option exercises included 108,334 and 17,001 shares, followed by sales such as 39,531, 39,332, 39,111, 17,001, and smaller lots. After the transactions, reported direct holdings included 109,190 shares, with additional indirect holdings across multiple family trusts, each listed with its own balance.

Hims & Hers Health (HIMS) CEO e proprietario del 10%, Andrew Dudum, ha comunicato multiple operazioni insider il 16/10/2025 ai sensi di un piano Rule 10b5-1 adottato il 28 agosto 2024. Ha esercitato opzioni su azioni a un prezzo di esercizio di $2.43 e ha venduto azioni in diverse tranche a prezzi medi ponderati divulgati all'interno di intervalli, tra cui $62.50–$62.87, $62.215–$63.13, e $63.31–$63.59.

Le esercitazioni di opzioni riportate includevano 108,334 e 17,001 azioni, seguite da vendite quali 39,531, 39,332, 39,111, 17,001, e lotti più piccoli. Dopo le operazioni, le partecipazioni dirette riportate includevano 109,190 azioni, con ulteriori partecipazioni indirette distribuite in vari trust familiari, ciascuno elencato con il proprio saldo.

Hims & Hers Health (HIMS) CEO y propietario del 10%, Andrew Dudum, informó de múltiples transacciones de insider el 16/10/2025 bajo un plan Rule 10b5-1 implementado el 28 de agosto de 2024. Ejercitó opciones sobre acciones a un precio de ejercicio de $2.43 y vendió acciones en varias tranchas a precios medios ponderados divulgados dentro de rangos, incluyendo $62.50–$62.87, $62.215–$63.13 y $63.31–$63.59.

Los ejercicios de opciones reportados incluyeron 108,334 y 17,001 acciones, seguidos de ventas tales como 39,531, 39,332, 39,111, 17,001 y lotes menores. Después de las transacciones, las participaciones directas reportadas incluyeron 109,190 acciones, con participaciones indirectas adicionales a través de múltiples fideicomisos familiares, cada uno listado con su saldo.

Hims & Hers Health (HIMS) CEO이자 10% 소유주인 Andrew Dudum은 2024년 8월 28일에 채택된 Rule 10b5-1 계획에 따라 2025년 10월 16일에 여러 내부자 거래를 보고했습니다. 그는 행사 가격 $2.43으로 주식 옵션을 행사했고, 가중 평균가가 범위 내에 공시된 여러 차례에 걸쳐 주식을 매각했으며, 포함 구간은 $62.50–$62.87, $62.215–$63.13, 및 $63.31–$63.59입니다.

보고된 옵션 행사에는 108,334주와 17,001주가 포함되었고, 그 뒤로 39,531, 39,332, 39,111, 17,001의 매도가 이어졌으며, 더 작은 매도도 있었습니다. 거래 후 보고된 직접 보유 주식 수는 109,190주였고, 여러 가족 신탁에 걸친 추가 간접 보유도 각 잔액과 함께 보고되었습니다.

Hims & Hers Health (HIMS) PDG et propriétaire à 10% Andrew Dudum a signalé plusieurs transactions d’initié le 16/10/2025 dans le cadre d’un plan Rule 10b5-1 adopté le 28 août 2024. Il a exercé des options sur actions à un prix d’exercice de $2.43 et a vendu des actions en plusieurs tranches à des prix moyens pondérés divulgués dans des fourchettes, notamment $62.50–$62.87, $62.215–$63.13, et $63.31–$63.59.

Les exercices d’options signalés comprenaient 108,334 et 17,001 actions, suivis de ventes telles que 39,531, 39,332, 39,111, 17,001, et des lots plus petits. Après les transactions, les participations directes signalées incluaient 109,190 actions, avec des participations indirectes supplémentaires réparties entre plusieurs fiducies familiales, chacune indiquée avec son solde.

Hims & Hers Health (HIMS) CEO und 10%-Eigentümer Andrew Dudum meldete am 16.10.2025 mehrere Insider-Transaktionen im Rahmen eines am 28.08.2024 eingeführten Rule 10b5-1-Plans. Er übte Aktienoptionen zu einem Ausübungspreis von $2.43 aus und verkaufte Aktien in mehreren Tranchen zu gemittelten Preisen, die innerhalb von Spannen offengelegt wurden, darunter $62.50–$62.87, $62.215–$63.13 und $63.31–$63.59.

Berichtete Optionsausübungen umfassten 108,334 und 17,001 Aktien, gefolgt von Verkäufen wie 39,531, 39,332, 39,111, 17,001 sowie kleinere Lots. Nach den Transaktionen beliefen sich die gemeldeten direkten Bestände auf 109,190 Aktien, mit zusätzlichen indirekten Beständen über mehrere Familientrusts, von denen jeder mit seinem Saldo aufgeführt ist.

Hims & Hers Health (HIMS) الرئيس التنفيذي ومالك 10% Andrew Dudum أبلغ عن عدة معاملات داخلية في 16/10/2025 وفقاً لخطة Rule 10b5-1 التي تم اعتمادها في 28 أغسطس 2024. مارس خيارات الأسهم بسعر تمارين قدره $2.43 وباع أسهماً على دفعات عدة بأسعار متوسطة مستخلصة ضمن نطاقات، بما في ذلك $62.50–$62.87، $62.215–$63.13، و$63.31–$63.59.

شملت عمليات خيارات موصوفة 108,334 و 17,001 سهمًا، تلتها صفقات بيع مثل 39,531، 39,332، 39,111، 17,001، ودفعات أصغر. بعد المعاملات، شملت الحيازات المباشرة المبلغ عنها 109,190 سهمًا، مع حيازات غير مباشرة إضافية عبر عدة أوقاف عائلية، كل منها مدرج مع رصيدها الخاص.

Hims & Hers Health (HIMS) 的首席执行官及持股10%的 Andrew Dudum 报告了在 2025-10-16 进行的多笔内部交易，依据于 2024-08-28 通过的 Rule 10b5-1 计划。他以行权价 $2.43 行使股票期权，并在若干批次中以披露的区间内的加权平均价格出售股票，包含 $62.50–$62.87、$62.215–$63.13，以及 $63.31–$63.59。

报告的期权行使包括 108,334 股和 17,001 股，随后有如 39,531、39,332、39,111、17,001 的出售，以及较小批次。交易结束后，报告的直接持股为 109,190 股，另有通过多项家庭信托的间接持股，分别以其余额列出。

Positive
  • None.
Negative
  • None.

Insights

Routine Form 4 under a pre-set 10b5-1 plan.

The CEO executed option exercises at an exercise price of $2.43 and sold shares in multiple trades on 10/16/2025. The filing states the activity was effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024, indicating pre-arranged instructions.

Weighted-average sale prices are provided in ranges (e.g., $62.50–$62.87 and $63.31–$63.59) with an undertaking to furnish full breakdowns upon request. This is standard disclosure and does not indicate issuer cash inflow.

Post-transaction, direct holdings are reported alongside multiple indirect trust holdings. Market impact depends on trade size relative to daily volume; actual effects will be determined by market conditions.

Hims & Hers Health (HIMS) CEO e proprietario del 10%, Andrew Dudum, ha comunicato multiple operazioni insider il 16/10/2025 ai sensi di un piano Rule 10b5-1 adottato il 28 agosto 2024. Ha esercitato opzioni su azioni a un prezzo di esercizio di $2.43 e ha venduto azioni in diverse tranche a prezzi medi ponderati divulgati all'interno di intervalli, tra cui $62.50–$62.87, $62.215–$63.13, e $63.31–$63.59.

Le esercitazioni di opzioni riportate includevano 108,334 e 17,001 azioni, seguite da vendite quali 39,531, 39,332, 39,111, 17,001, e lotti più piccoli. Dopo le operazioni, le partecipazioni dirette riportate includevano 109,190 azioni, con ulteriori partecipazioni indirette distribuite in vari trust familiari, ciascuno elencato con il proprio saldo.

Hims & Hers Health (HIMS) CEO y propietario del 10%, Andrew Dudum, informó de múltiples transacciones de insider el 16/10/2025 bajo un plan Rule 10b5-1 implementado el 28 de agosto de 2024. Ejercitó opciones sobre acciones a un precio de ejercicio de $2.43 y vendió acciones en varias tranchas a precios medios ponderados divulgados dentro de rangos, incluyendo $62.50–$62.87, $62.215–$63.13 y $63.31–$63.59.

Los ejercicios de opciones reportados incluyeron 108,334 y 17,001 acciones, seguidos de ventas tales como 39,531, 39,332, 39,111, 17,001 y lotes menores. Después de las transacciones, las participaciones directas reportadas incluyeron 109,190 acciones, con participaciones indirectas adicionales a través de múltiples fideicomisos familiares, cada uno listado con su saldo.

Hims & Hers Health (HIMS) CEO이자 10% 소유주인 Andrew Dudum은 2024년 8월 28일에 채택된 Rule 10b5-1 계획에 따라 2025년 10월 16일에 여러 내부자 거래를 보고했습니다. 그는 행사 가격 $2.43으로 주식 옵션을 행사했고, 가중 평균가가 범위 내에 공시된 여러 차례에 걸쳐 주식을 매각했으며, 포함 구간은 $62.50–$62.87, $62.215–$63.13, 및 $63.31–$63.59입니다.

보고된 옵션 행사에는 108,334주와 17,001주가 포함되었고, 그 뒤로 39,531, 39,332, 39,111, 17,001의 매도가 이어졌으며, 더 작은 매도도 있었습니다. 거래 후 보고된 직접 보유 주식 수는 109,190주였고, 여러 가족 신탁에 걸친 추가 간접 보유도 각 잔액과 함께 보고되었습니다.

Hims & Hers Health (HIMS) PDG et propriétaire à 10% Andrew Dudum a signalé plusieurs transactions d’initié le 16/10/2025 dans le cadre d’un plan Rule 10b5-1 adopté le 28 août 2024. Il a exercé des options sur actions à un prix d’exercice de $2.43 et a vendu des actions en plusieurs tranches à des prix moyens pondérés divulgués dans des fourchettes, notamment $62.50–$62.87, $62.215–$63.13, et $63.31–$63.59.

Les exercices d’options signalés comprenaient 108,334 et 17,001 actions, suivis de ventes telles que 39,531, 39,332, 39,111, 17,001, et des lots plus petits. Après les transactions, les participations directes signalées incluaient 109,190 actions, avec des participations indirectes supplémentaires réparties entre plusieurs fiducies familiales, chacune indiquée avec son solde.

Hims & Hers Health (HIMS) CEO und 10%-Eigentümer Andrew Dudum meldete am 16.10.2025 mehrere Insider-Transaktionen im Rahmen eines am 28.08.2024 eingeführten Rule 10b5-1-Plans. Er übte Aktienoptionen zu einem Ausübungspreis von $2.43 aus und verkaufte Aktien in mehreren Tranchen zu gemittelten Preisen, die innerhalb von Spannen offengelegt wurden, darunter $62.50–$62.87, $62.215–$63.13 und $63.31–$63.59.

Berichtete Optionsausübungen umfassten 108,334 und 17,001 Aktien, gefolgt von Verkäufen wie 39,531, 39,332, 39,111, 17,001 sowie kleinere Lots. Nach den Transaktionen beliefen sich die gemeldeten direkten Bestände auf 109,190 Aktien, mit zusätzlichen indirekten Beständen über mehrere Familientrusts, von denen jeder mit seinem Saldo aufgeführt ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dudum Andrew
(Last) (First) (Middle)
2269 CHESTNUT STREET, #523
(Street)
SAN FRANCISCO CA 94123
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/16/2025 S(1) 2,792 D $62.6518(2) 92,523 D
Class A Common Stock 10/16/2025 S(1) 39,111 D $62.6997(3) 55,947 I Held by Trustee of Dudum Family Community Property Trust
Class A Common Stock 10/16/2025 S(1) 8,423 D $63.4588(4) 47,524 I Held by Trustee of Dudum Family Community Property Trust
Class A Common Stock 10/16/2025 M(1) 17,001 A $2.43 109,524 D
Class A Common Stock 10/16/2025 S(1) 17,001 D $62.69(5) 92,523 D
Class A Common Stock 10/16/2025 M(1) 108,334 A $2.43 200,857 D
Class A Common Stock 10/16/2025 S(1) 39,531 D $62.7053(6) 161,326 D
Class A Common Stock 10/16/2025 S(1) 10,469 D $63.4852(7) 150,857 D
Class A Common Stock 10/16/2025 S(1) 39,332 D $62.6999(8) 111,525 D
Class A Common Stock 10/16/2025 S(1) 2,335 D $63.3873(9) 109,190 D
Class A Common Stock 10/16/2025 S(1) 16,667 D $62.6969(5) 92,523 D
Class A Common Stock 1,194,545 I Held by Trustee of AD 2022 GRAT 3 dated 11-28-2022
Class A Common Stock 1,016,871 I Held by Trustee of Andrew Dudum 2015 Trust Dated July 2, 2015
Class A Common Stock 1,286,627 I Held by Trustee of AD 2021 GRAT dated 11-1-2021
Class A Common Stock 186,723 I Held by Trustee of AD 2025 GRAT dated 5-27-2025
Class A Common Stock 508,030 I Held by Trustee of AD 2022 GRAT
Class A Common Stock 321,657 I Held by Trustee of AD 2021 GRAT 2 dated 11-1-2021
Class A Common Stock 1,584,506 I Held by Trustee of AD 2023 GRAT dated 9-5-2023
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $2.43 10/16/2025 M(1) 17,001 (10) 06/16/2030 Class A Common Stock 17,001 $0 17,005 D
Stock Option (right to buy) $2.43 10/16/2025 M(1) 108,334 (11) 06/16/2030 Class A Common Stock 108,334 $0 431,395 D
Explanation of Responses:
1. The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
2. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.50 - $62.87. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.215 - $63.13. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
4. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.31 - $63.59. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
5. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.25 - $62.94. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
6. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.22 - $63.18. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
7. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.25 - $63.63. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
8. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.22 - $63.20. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
9. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.26 - $63.47. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
10. Prior to the Company's business combination transaction in 2021, the option represented the right to purchase 7,166,182 shares of Hims, Inc. with an exercise price of $1.10. Following the Company's business combination transaction in 2021, the option converted into the right to purchase 3,246,139 shares of the Company with an exercise price of $2.43. 100% of the shares subject to the option vested upon certain specified thresholds met in 2021.
11. The Stock Option was received in exchange for an option to purchase 3,583,091 shares of Class A Common Stock of Hims, Inc., with an exercise price of $1.10, in connection with the Merger. 1/48 of the shares subject to the Stock Option vest when the Reporting Person completes each month of continuous Service beginning March 13, 2020.
Remarks:
/s/ Kimberly Mather, Attorney-in-Fact for Andrew Dudum 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did HIMS CEO Andrew Dudum report on Form 4?

He exercised stock options at an exercise price of $2.43 and sold shares in multiple tranches on 10/16/2025 under a Rule 10b5-1 plan.

Were the HIMS insider sales under a 10b5-1 plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024.

What price ranges did the HIMS insider sales occur at?

Weighted-average sale prices were disclosed in ranges including $62.50–$62.87, $62.215–$63.13, and $63.31–$63.59.

How many HIMS options were exercised by the CEO?

Reported exercises included 108,334 and 17,001 shares at an exercise price of $2.43.

What are the CEO’s reported direct HIMS holdings after the transactions?

The filing shows 109,190 shares held directly after the reported transactions.

Did the CEO have indirect HIMS holdings?

Yes. The filing lists multiple indirect holdings across family trusts, each reported with its own share balance.
Stock HIMS logo
Hims & Hers Health Inc

NYSE:HIMS

HIMS Rankings

#870 Ranked by Market Cap
N/A Ranked by Dividends

HIMS Latest News

Oct 15, 2025
Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026
Oct 13, 2025
Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025
Oct 9, 2025
Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor’s Office
Sep 10, 2025
Hims Launches New Category in Men’s Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments
Aug 4, 2025
Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

HIMS Latest SEC Filings

Oct 20, 2025
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity
Oct 16, 2025
[144] Hims & Hers Health, Inc. SEC Filing
Oct 14, 2025
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity
Oct 14, 2025
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity
Oct 10, 2025
[144] Hims & Hers Health, Inc. SEC Filing

HIMS Stock Data

11.16B
202.99M
10.63%
88.99%
33.02%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO